<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315678</url>
  </required_header>
  <id_info>
    <org_study_id>TR02-108</org_study_id>
    <nct_id>NCT01315678</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections</brief_title>
  <official_title>Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insmed Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A major factor in the respiratory health of Cystic Fibrosis (CF) participants is the
      prevalence of chronic Pseudomonas aeruginosa (Pa) infections. The Pa infection rate in CF
      patients increases with age and by age 18 years approximately 85% of CF patients in the US
      are infected. Liposomal amikacin for inhalation (Arikayce™) was developed as a possible
      treatment for chronic infection due to Pa in CF patients.

      The purpose of this study is to determine whether Arikayce™ is effective in treating chronic
      lung infections caused by Pa in CF participants. The effectiveness, safety, and tolerability
      of Arikayce™ will be compared to Tobramycin TOBI®, an inhalation antibiotic already available
      for use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CF is a genetic disease resulting from mutations in the cystic fibrosis transmembrane
      conductance regulator (CFTR) gene. Patients with CF manifest pathological changes in a
      variety of organs that express CFTR. The lungs are frequently affected often resulting in
      chronic infections by bacteria such as Pseudomonas aeruginosa and airway inflammation.
      Treatment of chronic lung infections is one of the principal goals of CF therapy. Arikayce™
      LAI (liposomal amikacin for inhalation) is a sustained-release formulation of amikacin
      encapsulated inside nanoscale liposomal carriers designed for administration via inhalation.
      It is hypothesized that the sustained-release pulmonary targeting and biofilm penetration
      properties of this formulation will have several advantages over current therapies in
      treating CF patients with chronic lung infection caused by Pseudomonas aeruginosa.

      This Phase 3 study has been designed to evaluate the efficacy, safety and tolerability of
      Arikayce™ in treating CF patients with chronic bronchopulmonary infection compared to a
      currently available antibiotic, TOBI® Inhalation Solution. Eligible participants will be
      randomized 1:1 to receive 590 mg of Arikayce™ once daily via a PARI Investigational eFlow®
      Nebulizer or 300 mg TOBI® BID via a PARI LC® PLUS nebulizer. Participants will receive 3
      cycles of treatment with each cycle being comprised of 28 days on treatment followed by 28
      days off-treatment. Total study duration is up to 186 days (~6 months) including an up to 18
      day Screening period. Participants will be evaluated for safety, tolerability and efficacy
      bi-weekly during the first 4 weeks of treatment, and thereafter every 4 weeks for the
      duration of the study. Pharmacokinetics (PK) of Arikayce™ in blood, sputum and 24-hour urine
      will be determined in a subgroup of study participants who consent to PK evaluation.

      At the completion of the TR02-108 protocol, participants who have consented and meet study
      safety criteria may enroll in the long-term, open-label, multi-cycle extension study of 590
      mg of Arikayce™ (under a separate protocol TR02-110). Arikace™, Arikayce™, Liposomal Amikacin
      for Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used
      interchangeably throughout this study and other studies evaluating amikacin liposome
      inhalation suspension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2012</start_date>
  <completion_date type="Actual">September 18, 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline to168 days</time_frame>
    <description>Relative Change (%) from baseline to end of study (Day 168) in FEV1 (1 second)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pumonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168.</time_frame>
    <description>Relative changes (%) from baseline to Study Days 14, 28, 57, 84, 113, 140, 168 in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Pulmonary Exacerbation</measure>
    <time_frame>168 days</time_frame>
    <description>Number of participants experiencing a pulmonary exacerbation measured by number with event and number censored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants to First Antipseudomonal Antibiotic Treatment for Pulmonary Exacerbation</measure>
    <time_frame>168 days</time_frame>
    <description>Number of participants to first antipseudomonal antibiotic treatment for pulmonary exacerbation measured by number with event and number censored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants to First All Cause Hospitalization</measure>
    <time_frame>168 days</time_frame>
    <description>Number of participants to first all cause hospitalization measured by number with event and number censored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Density (Log CFU) in Pseudomonas Aeruginosa in Sputum</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168</time_frame>
    <description>Change in density (Log CFU) from baseline in Pseudomonas aeruginosa in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Percent (%) Change in Respiratory Symptoms as Measured by the CFQ-R</measure>
    <time_frame>Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168</time_frame>
    <description>Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Pseudomonas Aeruginosa Infection</condition>
  <arm_group>
    <arm_group_label>Arikayce™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arikayce™ is liposomal amikacin for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOBI®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TOBI® is tobramycin inhalation solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.</intervention_name>
    <description>Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
    <arm_group_label>Arikayce™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin inhalation solution using a PARI LC® Plus nebulizer.</intervention_name>
    <description>300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
    <arm_group_label>TOBI®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written informed consent or assent

          -  Confirmed diagnosis of CF

          -  History of chronic infection with Pseudomonas aeruginosa

          -  Sputum culture positive for Pseudomonas aeruginosa at Screening

          -  FEV1 ≥ 25% of predicted value at Screening

        Key Exclusion Criteria:

          -  FEV1 &lt;25% of predicted at Screening

          -  History of major complications of lung disease within 8 weeks prior to Screening

          -  Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening

          -  History of positive culture for Burkholderia cepacia within 2 years prior to Screening

          -  History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease
             treated within 2 years prior to Screening or requiring treatment at the time of
             screening

          -  History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring
             systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months
             prior to Screening

          -  Presence of any clinically significant cardiac disease

          -  History of lung transplantation

          -  Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement
             of greater than 2 L/min

          -  Administration of any investigational products within 8 weeks prior to study Day 1

          -  Smoking tobacco or any substance within 6 months prior to screening or anticipated
             inability to refrain from smoking throughout the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Eagle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Insmed Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maroussi</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabka Zdroj</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penarth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <results_first_submitted>April 3, 2019</results_first_submitted>
  <results_first_submitted_qc>June 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2019</results_first_posted>
  <disposition_first_submitted>February 12, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 12, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 3, 2015</disposition_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Respiratory Infections</keyword>
  <keyword>Pulmonary Cystic Fibrosis</keyword>
  <keyword>CFTR</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Anti-bacterial Agents</keyword>
  <keyword>Amikacin liposome inhalation suspension (ALIS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>302 participants were randomized. 8 were not treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arikayce™</title>
          <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
        </group>
        <group group_id="P2">
          <title>TOBI®</title>
          <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>similar reason to those listed above</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arikayce™</title>
          <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
        </group>
        <group group_id="B2">
          <title>TOBI®</title>
          <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="146"/>
            <count group_id="B3" value="294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>6-12 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;12-18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="146"/>
                    <count group_id="B3" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>In TOBI arm , one patient was not recorded for ethnicity.</description>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="145"/>
                    <count group_id="B3" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Relative Change (%) from baseline to end of study (Day 168) in FEV1 (1 second)</description>
        <time_frame>Baseline to168 days</time_frame>
        <population>The PP is the primary analysis population for the primary efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arikayce™</title>
            <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
          </group>
          <group group_id="O2">
            <title>TOBI®</title>
            <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Relative Change (%) from baseline to end of study (Day 168) in FEV1 (1 second)</description>
          <population>The PP is the primary analysis population for the primary efficacy analysis</population>
          <units>Percent (%) change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="13.930"/>
                    <measurement group_id="O2" value="1.67" spread="16.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pumonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Relative changes (%) from baseline to Study Days 14, 28, 57, 84, 113, 140, 168 in FEV1</description>
        <time_frame>Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168.</time_frame>
        <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Arikayce™</title>
            <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
          </group>
          <group group_id="O2">
            <title>TOBI®</title>
            <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Pumonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Relative changes (%) from baseline to Study Days 14, 28, 57, 84, 113, 140, 168 in FEV1</description>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>percentage (%) change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="13.332"/>
                    <measurement group_id="O2" value="6.64" spread="15.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="14.745"/>
                    <measurement group_id="O2" value="3.32" spread="14.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.49" spread="12.319"/>
                    <measurement group_id="O2" value="0.70" spread="14.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="14.350"/>
                    <measurement group_id="O2" value="3.59" spread="14.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="12.028"/>
                    <measurement group_id="O2" value="0.42" spread="14.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="15.299"/>
                    <measurement group_id="O2" value="1.37" spread="16.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="14.326"/>
                    <measurement group_id="O2" value="1.58" spread="15.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a Pulmonary Exacerbation</title>
        <description>Number of participants experiencing a pulmonary exacerbation measured by number with event and number censored</description>
        <time_frame>168 days</time_frame>
        <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Arikayce™</title>
            <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
          </group>
          <group group_id="O2">
            <title>TOBI®</title>
            <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Pulmonary Exacerbation</title>
          <description>Number of participants experiencing a pulmonary exacerbation measured by number with event and number censored</description>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified Cox proportional hazards model</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0286</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants to First Antipseudomonal Antibiotic Treatment for Pulmonary Exacerbation</title>
        <description>Number of participants to first antipseudomonal antibiotic treatment for pulmonary exacerbation measured by number with event and number censored</description>
        <time_frame>168 days</time_frame>
        <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Arikayce™</title>
            <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
          </group>
          <group group_id="O2">
            <title>TOBI®</title>
            <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants to First Antipseudomonal Antibiotic Treatment for Pulmonary Exacerbation</title>
          <description>Number of participants to first antipseudomonal antibiotic treatment for pulmonary exacerbation measured by number with event and number censored</description>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6031</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants to First All Cause Hospitalization</title>
        <description>Number of participants to first all cause hospitalization measured by number with event and number censored</description>
        <time_frame>168 days</time_frame>
        <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Arikayce™</title>
            <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
          </group>
          <group group_id="O2">
            <title>TOBI®</title>
            <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants to First All Cause Hospitalization</title>
          <description>Number of participants to first all cause hospitalization measured by number with event and number censored</description>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number with Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4861</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Density (Log CFU) in Pseudomonas Aeruginosa in Sputum</title>
        <description>Change in density (Log CFU) from baseline in Pseudomonas aeruginosa in sputum</description>
        <time_frame>Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168</time_frame>
        <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Arikayce™</title>
          </group>
          <group group_id="O2">
            <title>TOBI®</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Density (Log CFU) in Pseudomonas Aeruginosa in Sputum</title>
          <description>Change in density (Log CFU) from baseline in Pseudomonas aeruginosa in sputum</description>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>Log 10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.872" spread="1.8806"/>
                    <measurement group_id="O2" value="6.510" spread="2.3202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.124" spread="2.0542"/>
                    <measurement group_id="O2" value="-1.663" spread="2.4017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.208" spread="2.1594"/>
                    <measurement group_id="O2" value="-1.453" spread="2.4440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>57 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.210" spread="1.9874"/>
                    <measurement group_id="O2" value="-0.098" spread="1.7446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.945" spread="2.2223"/>
                    <measurement group_id="O2" value="-1.182" spread="2.6914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>113 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.613" spread="2.1928"/>
                    <measurement group_id="O2" value="-0.135" spread="2.3461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>140 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.440" spread="2.4357"/>
                    <measurement group_id="O2" value="-1.315" spread="2.2300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.725" spread="2.0073"/>
                    <measurement group_id="O2" value="-0.136" spread="2.1750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Percent (%) Change in Respiratory Symptoms as Measured by the CFQ-R</title>
        <description>Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.</description>
        <time_frame>Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168</time_frame>
        <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
        <group_list>
          <group group_id="O1">
            <title>Arikayce™</title>
            <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
          </group>
          <group group_id="O2">
            <title>TOBI®</title>
            <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Percent (%) Change in Respiratory Symptoms as Measured by the CFQ-R</title>
          <description>Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.</description>
          <population>Modified intent-to-treat (mITT; received at least 1 dose of study drug)</population>
          <units>Percent (%) change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.65" spread="2.995"/>
                    <measurement group_id="O2" value="8.81" spread="3.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="138"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.54" spread="3.363"/>
                    <measurement group_id="O2" value="11.03" spread="3.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="3.120"/>
                    <measurement group_id="O2" value="7.97" spread="3.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.20" spread="3.079"/>
                    <measurement group_id="O2" value="8.55" spread="3.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="3.323"/>
                    <measurement group_id="O2" value="5.03" spread="3.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.84" spread="3.060"/>
                    <measurement group_id="O2" value="6.10" spread="3.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.06" spread="3.784"/>
                    <measurement group_id="O2" value="8.07" spread="3.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arikayce™</title>
          <description>Arikayce™ is liposomal amikacin for inhalation
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.</description>
        </group>
        <group group_id="E2">
          <title>TOBI®</title>
          <description>TOBI® is tobramycin inhalation solution
Tobramycin inhalation solution using a PARI LC® Plus nebulizer: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E2" events="28" subjects_affected="23" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="148"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="138" subjects_affected="82" subjects_at_risk="148"/>
                <counts group_id="E2" events="117" subjects_affected="72" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E2" events="43" subjects_affected="33" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="53" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E2" events="21" subjects_affected="10" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="148"/>
                <counts group_id="E2" events="24" subjects_affected="11" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="148"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Per the signed Investigator Agreement in the study protocol and protocol amendments, the PI agreed &quot;not to originate or use the name of Insmed Incorporated, or study drug code in any publicity, news release, or other public announcement, written or oral, whether to the public, press, or otherwise, relating to this protocol, to any amendment to the protocol, or to the performance of this protocol, without the prior written consent of Insmed Incorporated.&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Mange (Senior VP, Clinical Development and Medical Affairs)</name_or_title>
      <organization>Insmed Incorporated</organization>
      <phone>908-947-2651</phone>
      <email>kevin.mange@insmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

